| Literature DB >> 35836525 |
Jiaqi Zhang1, Jian Zhang1, Jun Ge1, Zheng Su1, Xiaolian Xiao1, Chen Chen1, Fen Shi1, Yongzhen Wang1, Jinming Zhang1, Weiqiang Liang1.
Abstract
Background: A defect caused by the radical resection of vulvar cancer requires repair with flap transplantation or vulvoplasty. However, in clinical practice, the surgeons encounter difficulties while using a flap to repair the wound. Therefore, this study aimed to present a review of our practice of post-surgical defect reconstruction in cases using different skin flaps.Entities:
Keywords: Vulvar tumor; local flap; pedicled flap; vulvar reconstruction
Year: 2022 PMID: 35836525 PMCID: PMC9273652 DOI: 10.21037/tcr-22-1421
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 0.496
Case details
| Case | Age (years) | Operation time(hour) | Adjuvant radiotherapy and chemotherapy | Basic disease | Tumor size(cm) | Urethral orifice or the anal orifice is involved | Tumor dimension (cm) | Lymph gland | Clinical stages | Cystostomy or colostomy | Pathological type | Operation method | Flap dimension (cm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 53 | 2.2 | Postoperative radiotherapy and chemotherapy | No | 2×2×1 | Urethral orifice is involved | 7×5 | No | Stage I | No | Squamous cell carcinoma | Bilateral rhomboid flap | 7×5+7×5 |
| 2 | 51 | 3.2 | Postoperative radiotherapy and chemotherapy | No | 2×2×1 | Urethral orifice is involved | 4×3 | No | Stage I | No | Squamous cell carcinoma | VRAM flap | 4×3 |
| 3 | 73 | 4.1 | Postoperative radiotherapy and chemotherapy | Hypertension | 7.5×6×3.5 | Urethral orifice is involved | 10×4.5 | ILND | Stage III | No | Squamous cell carcinoma | Rhomboid flap | 10×5 |
| 4 | 63 | 2.7 | Postoperative radiotherapy and chemotherapy | Hyperthyroidism | 1.5×1.3×1.1 | Urethral orifice is involved | 5×4.5 | No | Stage II | No | Squamous cell carcinoma | Rhomboid flap | 6×5 |
| 5 | 66 | 1.9 | Postoperative radiotherapy and chemotherapy | Hypertension and diabetes | 3×3×2 | the anal orifice is involved | 5×4 | ILND | Stage III | No | Sebaceous gland carcinoma | Bilateral V-Y flap | 5×4+5×4 |
| 6 | 65 | 2.3 | Postoperative radiotherapy and chemotherapy | No | 4.5×4.5×3.8 | Urethral orifice is involved | 7.5×6 | ILND | Stage II | No | Squamous cell carcinoma | Rhomboid flap | 8×6 |
| 7 | 51 | 2.4 | Postoperative radiotherapy and chemotherapy | No | 3×2.5×0.9 | No | 5×4 | No | Stage II | No | Squamous cell carcinoma | Rhomboid flap | 5×4 |
| 8 | 65 | 3.1 | Postoperative chemotherapy | Hypertension | 15×13×1 | Urethral orifice is involved | 18×16 | No | Stage III | No | Squamous cell carcinoma | Medial femoral flap | Left 20×9 + right 25×8 |
| 9 | 58 | 2.7 | No | No | 12×8×2 | Urethral orifice and the anal orifice is involved | 15×13 | No | Stage II | Colostomy | Squamous cell carcinoma | Medial femoral flap | Left 30×9 + right 27×8 |
| 10 | 71 | 2.5 | No | Hypertension | 4×3×3 | No | 6×5 | ILND | Stage III | No | Squamous cell carcinoma | Rhomboid flap | 6×5 |
| 11 | 55 | 2.1 | Postoperative radiotherapy and chemotherapy | Left lower extremity DVT | 13×12×4 | the anal orifice is involved | 14×14 | No | Stage II | Colostomy | Squamous cell carcinoma | Right medial femoral flap+ left anterolateral thigh flap | Left 17×7.5 + right 16×8 |
| 12 | 43 | 2.4 | Postoperative radiotherapy | No | 3×2×1 | No | 5.5×3 | ILND | Stage III | No | Squamous cell carcinoma | Rhomboid flap | 6×3.5 |
| 13 | 53 | 2.2 | Postoperative radiotherapy and chemotherapy | No | 25×9×6 | No | 26×10 | ILND | Stage IV | No | Squamous cell carcinoma | Right VRAM flap + left anterolateral thigh flap | Left 7×6 + right 26×5 |
| 14 | 47 | 2.1 | Postoperative chemotherapy | Hypertension | 5×4×3 | the anal orifice is involved | 6×5 | No | Stage II | both | Squamous cell carcinoma | Rhomboid flap | 6×5 |
| 15 | 63 | 2.3 | Postoperative chemotherapy | No | 12×6×1 | No | 14×8.5 | No | Stage III | No | Squamous cell carcinoma | Medial femoral flap | 15×10 |
| 16 | 34 | 3.1 | No | No | 3×4×3 | No | 5×4 | No | Stage II | No | Dermatofibrosarcoma protuberans | Rhomboid flap | 5×4 |
| 17 | 63 | 3.3 | Postoperative chemotherapy | No | 3×3×2 | Urethral orifice is involved | 5×4 | No | Stage II | No | Adenoid cystic carcinoma | Rhomboid flap | 5×4 |
| 18 | 40 | 3.4 | Postoperative radiotherapy and chemotherapy | No | 7×3.5×0.5 | No | 9×5 | No | Stage III | No | Dermatofibrosarcoma protuberans | Rhomboid flap | 10×5 |
| 19 | 28 | 2.6 | Postoperative radiotherapy and chemotherapy | Mild anemia & second trimester | 6×3×2 | No | 7.2×5 | ILND | Stage IV | No | Dermatofibrosarcoma protuberans | Medial femoral flap | 7.5×5 |
| 20 | 61 | 3.1 | Postoperative chemotherapy | No | 12×12×2 | Urethral orifice is involved | 15×15 | No | Stage IV | Cystostomy | Squamous cell carcinoma | V-Y flap | Left 4×4 + right 15×15 |
| 21 | 30 | 3.2 | No | No | 2.1×2.4×0.5 | No | 4×4 | No | Stage II | No | Squamous cell carcinoma | Rhomboid flap | 4×4 |
| 22 | 39 | 2.9 | Postoperative radiotherapy and chemotherapy | No | 4×2×1 | the anal orifice is involved | 5×3 | ILND | Stage III | Colostomy | Squamous cell carcinoma | Medial femoral flap | 5×3 |
| 23 | 55 | 3.1 | Postoperative radiotherapy | No | 13×11×3 | No | 14×13 | No | Stage III | No | Squamous cell carcinoma | Medial femoral flap | 15×15 |
| 24 | 64 | 4.2 | Postoperative radiotherapy and chemotherapy | Moderate anaemia | 14×9×1.5 | Urethral orifice is involved | 15×12 | ILND | Stage IV | No | Squamous cell carcinoma | V-Y flap | 15×12 |
| 25 | 72 | 1.9 | No | No | 3×1×0.5 | Urethral orifice is involved | 4.5×2.4 | ILND | Stage II | Cystostomy | Squamous cell carcinoma | Modified rhomboid flap | 5×3 |
| 26 | 54 | 2.1 | Preoperative chemotherapy | No | 8×5×1 | the anal orifice is involved | 10×7 | No | Stage III | No | Squamous cell carcinoma | Bilateral V-Y flap | 10×7+10×7 |
DVT, deep venous thrombosis; ILND, inguinal lymph node dissection; VRAM, vertical rectus abdominis myocutaneous.
Clinical data
| Characteristic | Data |
|---|---|
| Age, years, mean ± SD [range] | 54.5±12.7 [28–73] |
| Mean interval of disease before surgery | |
| Years, mean ± SD [range] | 4.2±1.9 [2–9] |
| Clinical stage, number (%) | |
| I | 2 (7.7) |
| II | 10 (38.5) |
| III | 10 (38.5) |
| IV | 4 (15.4) |
| Site, number (%) | |
| Perineum without | |
| Vagina/urethra/anus | 16 (61.5) |
| Perineum with anus | 5 (19.2) |
| Perineum with vagina | 8 (30.8) |
| Perineum with urethra | 2 (7.7) |
| Perineum and pubic mound | 10 (38.5) |
| Surgical techniques, number (%) | |
| Rhomboid flap | 13 (50.0) |
| V-Y flap | 4 (15.4) |
| Medial femoral flap | 6 (23.1) |
| VRAM flap | 1 (3.9) |
| Combined flap | 2 (7.7) |
| Follow up, months, mean ± SD [range] | 35.2±11.5 [15–50] |
VRAM, vertical rectus abdominis myocutaneous.
Figure 1Female, 66 Y. (A) The size of the wound after vulvar sebaceous gland carcinoma expansion is 5 cm × 4 cm. (B) Design of a bilateral V-Y flap, 5 cm × 4 cm + 5 cm × 4 cm. (C) The flap completely covers the wound.
Figure 2Female, 53 Y. (A) The size of the wound after vulvar squamous cell carcinoma expansion is 7 cm × 5 cm. (C) Design of a bilateral rhomboid flap, 7 cm × 5 cm + 7 cm × 5 cm. (D) The flap completely covers the wound.
Figure 3Female, 51 Y. (A) The size of the wound after vulvar squamous cell carcinoma expansion is 4 cm × 3 cm. (B) Design of a VRAM flap, 4 cm × 3 cm. The flap completely covers the wound. (C) Two weeks after surgery. VRAM, vertical rectus abdominis myocutaneous.
Figure 4Female, 71 Y. (A) The size of the wound after vulvar squamous cell carcinoma expansion is 6 cm × 5 cm. (B) Design of a rhomboid flap, 6 cm × 5 cm. (C) The flap completely covers the wound. (D) Two weeks after surgery.